ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 247 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.36 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,328,933 | -12.9% | 255,707 | +0.1% | 0.01% | 0.0% |
| Q2 2023 | $6,117,668 | +34.7% | 255,435 | +5.9% | 0.01% | +16.7% |
| Q1 2023 | $4,541,511 | +18.1% | 241,313 | -0.1% | 0.01% | +20.0% |
| Q4 2022 | $3,845,683 | -0.3% | 241,563 | +2.4% | 0.01% | -16.7% |
| Q3 2022 | $3,857,655 | -14.7% | 235,798 | -26.5% | 0.01% | -45.5% |
| Q2 2022 | $4,522,000 | +286.8% | 320,926 | +565.1% | 0.01% | +450.0% |
| Q1 2022 | $1,169,000 | +4.0% | 48,253 | +0.2% | 0.00% | 0.0% |
| Q4 2021 | $1,124,000 | +41.6% | 48,148 | +0.8% | 0.00% | 0.0% |
| Q3 2021 | $794,000 | -30.9% | 47,779 | +1.4% | 0.00% | 0.0% |
| Q2 2021 | $1,149,000 | -44.2% | 47,135 | -41.0% | 0.00% | -50.0% |
| Q1 2021 | $2,060,000 | -25.4% | 79,851 | +54.5% | 0.00% | -33.3% |
| Q4 2020 | $2,763,000 | +28.1% | 51,689 | -1.1% | 0.01% | +20.0% |
| Q3 2020 | $2,157,000 | -5.2% | 52,281 | +11.4% | 0.01% | 0.0% |
| Q2 2020 | $2,275,000 | -11.1% | 46,936 | -22.5% | 0.01% | -28.6% |
| Q1 2020 | $2,559,000 | -2.1% | 60,574 | -0.9% | 0.01% | +40.0% |
| Q4 2019 | $2,615,000 | +71.4% | 61,133 | +44.2% | 0.01% | +66.7% |
| Q3 2019 | $1,526,000 | +26.6% | 42,394 | -5.9% | 0.00% | 0.0% |
| Q2 2019 | $1,205,000 | -1.7% | 45,066 | -1.3% | 0.00% | 0.0% |
| Q1 2019 | $1,226,000 | +88.0% | 45,648 | +13.2% | 0.00% | +50.0% |
| Q4 2018 | $652,000 | -17.2% | 40,341 | +6.5% | 0.00% | 0.0% |
| Q3 2018 | $787,000 | +35.9% | 37,888 | 0.0% | 0.00% | +100.0% |
| Q2 2018 | $579,000 | -72.7% | 37,888 | -59.9% | 0.00% | -80.0% |
| Q1 2018 | $2,123,000 | -17.0% | 94,502 | +11.2% | 0.01% | 0.0% |
| Q4 2017 | $2,559,000 | +43.2% | 85,008 | +79.2% | 0.01% | +25.0% |
| Q3 2017 | $1,787,000 | +69.7% | 47,447 | +25.6% | 0.00% | +100.0% |
| Q2 2017 | $1,053,000 | -21.2% | 37,769 | -2.8% | 0.00% | -33.3% |
| Q1 2017 | $1,336,000 | +14.3% | 38,863 | -4.2% | 0.00% | 0.0% |
| Q4 2016 | $1,169,000 | -86.4% | 40,550 | -85.0% | 0.00% | -81.2% |
| Q3 2016 | $8,607,000 | -63.0% | 270,581 | -62.3% | 0.02% | -71.9% |
| Q2 2016 | $23,269,000 | -3.0% | 716,858 | -16.5% | 0.06% | -3.4% |
| Q1 2016 | $23,992,000 | -7.1% | 858,114 | +18.4% | 0.06% | -6.3% |
| Q4 2015 | $25,827,000 | +7.4% | 724,464 | -0.4% | 0.06% | +5.0% |
| Q3 2015 | $24,053,000 | -23.7% | 727,339 | -3.4% | 0.06% | -16.7% |
| Q2 2015 | $31,531,000 | +2144.2% | 752,889 | +1646.5% | 0.07% | +2300.0% |
| Q1 2015 | $1,405,000 | +2.6% | 43,109 | 0.0% | 0.00% | 0.0% |
| Q4 2014 | $1,369,000 | +28.3% | 43,109 | 0.0% | 0.00% | +50.0% |
| Q3 2014 | $1,067,000 | +9.5% | 43,109 | 0.0% | 0.00% | 0.0% |
| Q2 2014 | $974,000 | -7.1% | 43,109 | 0.0% | 0.00% | 0.0% |
| Q1 2014 | $1,049,000 | -2.6% | 43,109 | 0.0% | 0.00% | 0.0% |
| Q4 2013 | $1,077,000 | -4.3% | 43,109 | +5.3% | 0.00% | -33.3% |
| Q3 2013 | $1,125,000 | +51.4% | 40,957 | 0.0% | 0.00% | +50.0% |
| Q2 2013 | $743,000 | – | 40,957 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |